Aprameya Medtech Partners with SonoScape for Exclusive Sales and Marketing of Advanced Surgical Imaging Systems

Aprameya Medtech Partners with SonoScape for Exclusive Sales and Marketing of Advanced Surgical Imaging Systems​

Aprameya Engineering Limited, a leading healthcare infrastructure company, has announced a strategic alliance through its subsidiary, Aprameya Medtech Private Limited. The partnership involves bringing SonoScape Medical Corp.'s advanced Minimally Invasive Surgery (MIS) portfolio to the market exclusively across Southern and Western India. This move is set to significantly transform Aprameya's business model by integrating high-value medical equipment into its existing hospital infrastructure franchise.

Aprameya Engineering Limited, which specializes in turnkey solutions for critical healthcare units such as ICUs, NICUs, and Operating Theatres, reported that its 70%-owned subsidiary, Aprameya Medtech Private Limited, has entered the exclusive sales and marketing agreement with Sonoscape Medical India Private Limited (the entity representing SonoScape, China). This alliance establishes a premium technology-led product line alongside Aprameya’s proven hospital buildout expertise.

The partnership aims to move Aprameya from a project-led business toward an integrated Healthcare Infrastructure and Medical Equipment platform, leveraging its established relationships in construction with a world-class medical equipment provider. The two companies have also indicated intentions to evaluate manufacturing these systems within India in the future, supporting the 'Make in India' vision.

SonoScape Technology Overview​

The advanced MIS portfolio provided by SonoScape is designed to replace large open incisions with tiny ports, guided entirely by high-definition camera systems. This technology allows hospitals across India to upgrade their surgical capabilities, leading to faster patient recovery and increased surgical volumes.

Aprameya Medtech will offer products tailored to various hospital segments:

The Global Partner​

SonoScape Medical Corp., which was founded in 2002 and is headquartered in Shenzhen, is a globally listed medical imaging company serving clinicians in over 170 countries. SonoScape is noted as one of only a few companies worldwide to integrate ultrasound, endoscopy, surgical visualization, and interventional imaging under a single platform. The company backs this capability with seven global R&D centres, over 800 R&D engineers, and more than 1,035 patents.

Strategic Growth Drivers​

The partnership offers several strategic advantages to Aprameya:

• Market Opportunity: Industry estimates project the minimally invasive surgical devices market in India to nearly double by 2033, driven by rising insurance penetration, hospital capital expenditure (capex), and medical tourism.
• Revenue Quality Upgrade: Branded equipment sales, supported by a recurring layer of service and consumables, introduce a repeatable, higher-margin income stream that complements Aprameya’s project revenue base.
• Integrated Customer Base: Aprameya already builds the operating theatres and ICUs where these systems are used; this existing infrastructure allows for fully integrated OR solutions few competitors can replicate.
• Geographic Expansion: The partnership focuses on Southern and Western India, which helps diversify the Company’s dependence away from any single state ecosystem.

Scope and Future Plans​

The engagement extends beyond simply installing equipment. Aprameya Medtech is committed to developing a dedicated MIS vertical that includes clinical demonstrations, surgeon training, application support, installation integrated into its turnkey hospital projects, and comprehensive after-sales service and maintenance across the partnership territory.

Furthermore, in anticipation of future operational readiness, Aprameya Medtech is constructing a facility spanning approximately 45,000 sq. ft., which is expected to become operational by the end of CFY 2026-27. This facility will position Aprameya for localizing production over time, thereby improving margins and service delivery in government procurement avenues.

Aprameya believes that with a strengthened balance sheet, an active bid pipeline, and the addition of this premium surgical technology portfolio, it is well positioned for scalable growth in CFY 2026-27 and beyond. The Company intends to keep investors updated on the progress of the partnership operationalization and the India manufacturing program.

APRAMEYA Stock Price Movement​

Aprameya Engineering Limited saw its stock edge higher today, closing at ₹160.00 after gaining 0.66%. The equity traded within an intraday range spanning from a low of ₹158.00 to a high of ₹162.50.